Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IDT Biologika

- PMLiVE

Eli Lilly and Incyte’s Olumiant approved by FDA for hospitalised COVID-19 patients

Nearly one million people with COVID-19 have been treated with Olumiant in approximately 15 countries worldwide

- PMLiVE

UK trial of fourth vaccine dose shows increased protection against COVID-19

The results of the study showed the booster vaccine was particularly effective in those over 70

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

FDA limits use of Janssen’s COVID-19 vaccine

Authorisation of Janssen COVID-19 vaccine restricted among certain people following analysis and evaluation

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

The drug combination offers biliary tract cancer patients a new treatment option

- PMLiVE

STORM Therapeutics receives Innovate UK grant

The grant will be used to research and develop a new coronavirus therapy

- PMLiVE

AstraZeneca unveils plans for new US R&D centre

The site, scheduled for completion in 2026, will also include the headquarters of Alexion

- PMLiVE

New study highlights significance of chronic obstructive pulmonary disease flare-ups

COPD causes nearly 30,000 deaths in England each year, with an annual overall cost to the NHS of £1.9bn

- PMLiVE

FDA approves COVID-19 treatment for those under the age of 12

Veklury is currently the only COVID-19 treatment approved for this age group

- PMLiVE

Gilead’s Veklury significant decreases risk of hospitalisation for COVID-19 patients

Using Veklury within five days of symptom onset – or between five to seven days of symptom onset – reduced hospitalisations in patients at high risk for severe COVID-19 disease

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links